LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on ATXS stock, giving a Buy rating today.
Sam Slutsky has given his Buy rating due to a combination of factors that highlight Astria Therapeutics’ promising developments and strategic advancements. The company has made significant strides in the hereditary angioedema (HAE) treatment landscape, particularly with the initiation of the Phase 3 ALPHA-ORBIT trial for navenibart, a long-acting plasma kallikrein inhibitor. This trial is designed as a single-trial registration path, which includes a primary analysis over six months and a long-term extension portion, indicating a well-structured approach to clinical development.
Furthermore, Astria’s execution in 2024 demonstrated strong proof-of-concept data in earlier phases, which supports a high probability of success for the ongoing pivotal trial. The company’s financial position, with approximately 2.5 years of cash runway, also provides a stable foundation for continued research and development. These elements collectively underpin Slutsky’s confidence in Astria’s potential for future growth and success, justifying the Buy rating.
According to TipRanks, Slutsky is an analyst with an average return of -6.8% and a 31.23% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Immunovant, Astria Therapeutics, and Spyre Therapeutics.
In another report released today, JMP Securities also reiterated a Buy rating on the stock with a $26.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com